


敬死扶伤，不辞艰辛，恪守医德，维护医术的圣洁和荣誉。

饶贤才*

编辑: dhj 发布时间: 2020-07-09 10:02

◎ 4759



主任/教授

学习经历

2007.03-2008.11 美国波士顿大学医学院 博士后
1999.09-2002.12 第三军医大学微生物学 博士生
1992.09-1995.07 第三军医大学微生物学 硕士生
1986.09-1990.07 第三军医大学医学检验专业 本科

工作经历

2018.01-今 陆军军医大学微生物学教研室 主任, 教授
2010.07-2017.12 第三军医大学微生物学教研室 主任, 教授
2006.09-2010.06 第二军医大学微生物学教研室 副主任, 教授
2001.09-2006.08 第三军医大学微生物学教研室 副主任, 副教授
1996.09-2001.08 第三军医大学微生物学教研室 讲师
1990.08-1996.08 第三军医大学微生物学教研室 助教

研究方向、教学课程

研究方向: 微生物致病机理与耐药性。重点针对多耐药金黄色葡萄球菌耐药性, 尤其是万古霉素耐药性开展研究, 针对金葡萄和革革病菌的致病机理进行研究, 探讨病原与宿主相互作用, 建立抗感染治疗新手段。

教授课程: 1.《医学微生物学》(通讲)

2.《实验室安全与防护》(研究生课程, 教学组长)

3.《生命科学综合IV: 生物医学前沿技术》(研究生课程, 组长)

4.《分子微生物学》(研究生课程)

成果: 1.文章2.专利3.项目4.获奖**1.论文 (通讯作者或第一作者)**

- 1) Yang Y, Shang W, Rao X. Facing the COVID-19 outbreak: What should we know and what could we do? *J Med Virol.* 2020; 92(6):536-537. (IF 2.012)
2) Shang W, Yang Y, Rao X, Rao X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. *npj Vaccines.* 2020; 5:18. (IF 5.699)
3) Yang Y, Wang H, Zhou H, Hu Z, Shang W, Rao Y, Peng H, Zheng Y, Hu Q, Zhang R, Luo R, Rao X. Protective effect of the golden staphyloxyanthin biosynthetic pathway on *Staphylococcus aureus* under cold atmospheric plasma treatment. *Appl Environ Microbiol.* 2020; 86(3): e01998-19. (IF 4.016)
4) Cong Y, Yang S, Rao X. Vancomycin resistant *Staphylococcus aureus* infections: A review of case updating and clinical features. *J Adv Res.* 2020; 21:169-176. (IF 6.992)
5) Shang W, Rao Y, Zheng Y, Yang Y, Hu Q, Hu Z, Yuan J, Peng H, Xiong H, Tan L, Li S, Zhu J, Li M, Hu X, Mao X, Rao X. β -Lactam antibiotics enhance the pathogenicity of methicillin-resistant *Staphylococcus aureus* via SarA-controlled lipoprotein like cluster expression. *mBio.* 2019; 10(3): e00880-19. (IF 6.782)
6) Zheng Y, Shang W, Peng H, Rao Y, Zhao X, Hu Z, Yang Y, Hu Q, Tan L, Xiong K, Li S, Zhu J, Hu X, Zhou R, Li M, Rao X. Virulence determinants are required for brain abscess formation through *Staphylococcus aureus* infection and are potential targets of antivirulence factor therapy. *Front Microbiol.* 2019; 10:682. (IF 4.235)
7) Peng H, Rao Y, Yuan W, Zheng Y, Shang W, Hu Z, Yang Y, Tan L, Xiong K, Li S, Zhu J, Hu X, Hu R, Rao X. Reconstruction of the Vancomycin-Susceptible *Staphylococcus aureus* Phenotype From a Vancomycin-Intermediate *S. aureus* XN108. *Front. Microbiol.* 2018; 9: 2955. (IF 4.259)
8) Liu H, Shang W, Hu Z, Zheng Y, Yuan J, Hu Q, Peng H, Cai X, Tan L, Li S, Zhu J, Li M, Hu X, Zhou R, Rao X. Yang Y. A novel *SigB*(Q225P) mutation in *Staphylococcus aureus* retains virulence but promotes biofilm formation. *Emerg Microbes Infect.* 2018; 7(1):72. (IF 6.212)
9) Yang Y, Yang J, Rao X. What role does superficial *Vimentin* have during DENV-2 infection? *Future Virol.* 2018; 13(3):151-154. (IF 1.121)
10) Yuan J, Yang J, Hu Z, Yang Y, Shang W, Hu Q, Zheng Y, Peng H, Zhang X, Cai X, Zhu J, Li M, Hu X, Zhou R, Rao X. Safe staphylococcal platform for the development of multivalent nanoscale vesicles against viral infections. *Nano Lett.* 2018; 18(2):725-733. (IF 12.279)
11) Yu H, Rao X, Zhang K. Nucleoside diphosphate kinase (Ndk): A pleiotropic effector manipulating bacterial virulence and adaptive responses. *Microbiol Res.* 2017; 205:125-134. (IF 2.777)
12) Zhang X, Hu X, Rao X. Apoptosis induced by *Staphylococcus aureus* toxins. *Microbiol Res.* 2017; 205:19-24. (IF 2.777)
13) Li M, Shen X, Zhao Y, Hu X, Hu F, Rao X. Better understanding of homologous recombination through a 12-week laboratory course for undergraduates majoring in biotechnology. *Biochem Mol Biol.* 2017; 45(4):329-335. (IF 1.036)
14) Peng H, Hu Q, Shang W, Zheng Y, Yuan J, Hu Q, Peng H, Cai X, Tan L, Li S, Hu X, Zhou R, Rao X, Wei K(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108. *Antimicrob Chemother.* 2017; 72(4):1006-1013. (IF 5.217)
15) Yang Y, Hu Z, Shang W, Hu Q, Zhu J, Yang J, Peng H, Zhang X, Liu H, Cong Y, Li S, Hu X, Zhou R, Rao X. Molecular and phenotypic characterization revealed high prevalence of multidrug-resistant methicillin-susceptible *Staphylococcus aureus* in Chongqing, Southwestern China. *Microb Drug Resist.* 2017; 23(2):241-246. (IF 2.344)
16) Yang J, Zou L, Yang Y, Yuan J, Hu Z, Liu H, Peng H, Shang W, Zhang X, Zhu J, Rao X. Superficial *vimentin* mediates DEN-2 infection of vascular endothelial cells. *Sci Rep.* 2016; 6:38372. (IF 5.228)
17) Hu Q, Peng H, Rao X. Molecular events for promotion of vancomycin resistance in vancomycin intermediate *Staphylococcus aureus*. *Front Microbiol.* 2016; 7:1601. (IF 4.076)
18) Zhang X, Shang W, Yuan J, Hu Z, Peng H, Zhu J, Hu Q, Yang Y, Liu H, Jiang B, Wang Y, Li S, Hu X, Rao X. Positive feedback cycle of TNF α promotes staphylococcal enterotoxin B-induced THP-1 cell apoptosis. *Front Cell Infect Microbiol.* 2016; 6:109. (IF 5.218)
19) Li M, Hu X, Hu F, Rao X. Beyond the classroom lecture: Liang Wang's personal war on tuberculosis in China. *Protein Cell.* 2016; 7(10):697-698. (IF 5.374)
20) Liu H, Zhu J, Hu Q, Rao X, Morganella morganii, a non-negligent opportunistic pathogen. *Int J Infect Dis.* 2016; 50:10-17. (IF 2.532)
21) Yu H, Xiong J, Zhang R, Hu Q, Xiong J, Zhang D, Xu X, Xie R, He X, Xie W, Sheng H, Chen O, Zhang L, Rao X, Zhang K, Ndk, a novel host-responsive regulator, negatively regulates bacterial virulence through quorum sensing in *Pseudomonas aeruginosa*. *Sci Rep.* 2016; 6:28684. (IF 4.259)
22) Rao Q, Shang W, Hu X, Rao X. *Staphylococcus aureus* ST121: A globally disseminated hypervirulent clone. *J Med Microbiol.* 2015; 64(12):1462-73. (IF 2.269)
23) Shang W, Hu Q, Yuan W, Cheng H, Yang J, Hu Z, Yuan J, Zhang X, Peng H, Yang Y, Hu X, Li M, Zhou R, Rao X. Comparative fitness and determinants for the characteristic drug resistance of ST239-MRSA-III-t030 and ST239-MRSA-III-t037 strains isolated in China. *Microb Drug Resist.* 2016; 22(3):185-92. (IF 2.306)
24) Xiong K, Chen Z, Zhu C, Li J, Hu X, Rao X, Cong Y. Safety and immunogenicity of an attenuated *Salmonella enterica* serovar Paratyphi A vaccine candidate. *Int J Med Microbiol.* 2015; 305(6):563-71. (IF 3.898)
25) Rao Q, Shang W, Zhou K, Zhou R, Rao X. Fatal multiple organ failure in an adolescent due to community-acquired methicillin-susceptible *Staphylococcus aureus* ST121/agrIV lineage: Case report and review. *Rev Med Microbiol.* 2015; 26(4): 163-167. (IF 0.705)
26) Hu Q, Cheng H, Yuan W, Zeng F, Shang W, Tang W, Dang X, Xue W, Fu J, Zhou R, Zhu J, Yang J, Hu Z, Yuan J, Zhang X, Rao Q, Li S, Chen Z, Hu X, Wu X, Rao X, Pantón—Valentine leukocidin (PVL)-positive healthcare-associated methicillin-resistant *Staphylococcus aureus* isolates are associated with skin and soft tissue infections and colonized mainly by infective PVL-encoding bacteriophages. *J Clin Microbiol.* 2015; 53(1):67-72. (IF 3.631)
27) Zhang X, Xu X, Yuan W, Hu Q, Shang W, Tong Y, Rao X. Complete Genome Sequence of *Staphylococcus aureus* XN108, an ST239-MRSA-III strain with Intermediate-Level Vancomycin Resistance Isolated in Mainland China. *Genome Announc.* 2014, 2(4):e00449-14.
28) Zhang X, Hu Q, Yuan W, Shang W, Cheng H, Yuan J, Zhu J, Hu Z, Li S, Chen W, Hu X, Rao X. First report of a sequence type 239 vancomycin-intermediate *Staphylococcus aureus* isolate in Mainland China. *Diagn Microbiol Infect Dis.* 2013; 77(1):64-8. (IF 2.568)
29) Cheng H, Yuan W, Zeng F, Hu Q, Shang W, Tang D, Xue W, Fu J, Liu J, Liu N, Zhu J, Yang J, Hu Z, Yuan J, Zhang X, Rao Q, Li S, Chen Z, Hu X, Wu X, Rao X. Molecular and phenotypic evidence for the spread of three major methicillin-resistant *Staphylococcus aureus* clones associated with two characteristic antimicrobial resistance profiles in China. *J Antimicrob Chemother.* 2013; 68(11):2453-7. (IF 2013 5.439)
30) Yang J, Zou L, Hu Z, Chen W, Zhang J, Zhu J, Fang X, Yuan W, Hu X, Hu F, Rao X. Identification and characterization of a 43 kDa actin protein involved in the DENV-2 binding and infection of ECV30 cells. *Microbes Infect.* 2013; 15(4):310-318. (IF 2013 2.731)
31) Yuan W, Hu Q, Cheng H, Shang W, Liu N, Hu Z, Zhu J, Hu Z, Yuan J, Zhang X, Li S, Chen Z, Hu X, Fu J, Rao X. Cell wall thickening is associated with adaptive resistance to amikacin in methicillin-resistant *Staphylococcus aureus* clinical isolates. *J Antimicrob Chemother.* 2013; 68(5):1089-1096. (IF 5.439)
32) Fang X, Hu Z, Shang W, Zhu J, Xu C, Rao X. Genetic polymorphisms of molecules involved in host immune response for Dengue virus infection. *FEMS Immunol Med Microbiol.* 2012; 66(2):134-46 (IF 2.684)
33) Shang W, Liu J, Hu Z, Yang J, Zhu J, Rao X. Dengue virus-like particles: construction and application. *Appl Microbiol Biotechnol.* 2012; 94(1):39-46. (IF 3.689)
34) Yang J, Zhang J, Chen W, Hu Z, Liu J, Fang X, Yuan W, Hu X, Hu F, and Rao X. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in *Escherichia coli*. *Can J Microbiol.* 2012; 58 (4): 369-80. (IF 1.199)
35) Wang D, Chen Z, Hu Z, Yuan W, Rao X. A recombinant antimicrobial peptide inhibits the growth of oxacillin-induced L-forms of *Staphylococcus aureus*. *Int J Antimicrob Ag.* 2011; 38(2):177-178. (IF 4.128)
36) Chen Z, Wang D, Cong Y, Wang J, Zhu J, Yang J, Hu Z, Tan Y, Hu F, Rao X. Recombinant antimicrobial peptide hPAB- β expressed in *Pichia pastoris*, a potential agent active against methicillin-resistant *Staphylococcus aureus*. *Appl Microbiol Biot.* 2011; 89(2):281-291. (IF 3.280)
37) Zhu J, Rao X, Tan Y, Xiong K, Hu Z, Chen Z, Jin X, Li S, Chen Y, Hu F. Identification of a lytic Bacteriophage Mmp1, assigned to a new member of T7-like phages infecting *Morganella morganii*. *Genomics.* 2010; 96:167-172 (共同第一, IF 4.087)
38) Rao X, Delghan P, Hu Z, Hu X, Wang J, Luo M, Wang J, Liang Y, Zhong G, Hochschild A, Shen L. A regulator from *Chlamydia trachomatis* modulates the activity of RNA polymerase through direct interaction with the β subunit and the primary σ subunit. *Genes Dev.* 2009, 23 (15) : 1818-1829. (IF 13.623)
39) Rao X, Hu J, Li S, Jin X, Zhang C, Cong Y, Hu X, Tan Y, Huang J, Chen Z, Zhu J, Hu F. Design and expression of peptide antibiotic hPAB- β as tandem multimers in *E. coli*. *Peptides.* 2005; 26(5): 721-729. (IF 2.635)
40) Rao XC, Li S, Hu JC, Jin XL, Hu XM, Huang JJ, Chen ZJ, Zhu JM, Hu FQ. A novel carrier molecule for high-level expression of peptide antibiotics in *Escherichia coli*. *Protein Expr Purif.* 2004; 36(1):11-16. (IF 1.47)
41) Rao XC, Hu XM, Jin XL, Huang JJ, Li S, Chen ZJ, Zhu JM, Hu JC, Hu FQ. Cpn0809 gene: another useful target for detection of *Chlamydophila pneumoniae* by PCR. *Ann Microbiol.* 2004; 54(1): 115-125. (IF 0.53)

2.专利

1) 饶贤才, 袁吉振, 杨杰, 胡珍, 胡晓梅, 尚伟龙, 朱军民. 一种金黄色葡萄球菌膜泡展示系统及其制备方法和应用, 专利号: ZL201510945536.5, 2019授权

2) 饶贤才, 袁吉振, 杨杰, 胡珍, 胡晓梅, 陈伟. 金黄色葡萄球菌类变株及其制备方法和应用, 专利号: ZL 201310286005.0, 2014授权

3) 饶贤才, 杨杰; 胡珍; 胡晓梅; 陈伟. 一种登革病毒简并疫苗及其制备方法和应用. 专利号: ZL 201310140259.1, 2014授权

4) 饶贤才, 杨杰, 张俊磊, 胡珍, 裴文斌. 登革病毒单克隆抗体及其制备方法. 国家发明专利. 201110112898.8, 2012授权

5) 胡福泉, 胡福泉, 胡珍, 朱军民, 陈志瑾, 杨杰. 登革病毒D-H5a的f1基因敲除突变株及其制备方法和应用, 专利号: ZL 201010600832.9, 2013授权

6) 胡福泉, 胡福泉, 胡珍, 李明, 乐军. 一种用于肿瘤局部介入治疗的TAT-P-EII融合蛋白及制备方法. 申请号: 200710092463.5

7) 胡福泉, 胡福泉, 胡珍, 李明. 多拷贝串联人胱氨酸hPAB的制备 申请号: 2004100075343

8) 胡福泉, 胡福泉, 胡珍. 一种高效表达生产胱氨酸素的方法. 专利号: ZL 01131855. 2004年授权

3.承担的项目

1) 军队XXX重大专项项目: “XXXXX免疫筛查分析技术与产品研究”, 2017.10-2020.12.课题编号17SAZ08, 经费1000万元 (主持).

2) 基础-临床融合研究项目: “城邦酰化修饰影响金黄色葡萄球菌中等耐受万古霉素中的作用与机制”, 2019.12-2022.11.课题编号: 2019JCLC01, 经费20万元 (主持)

3) 国家重点研发专项 “重要病原体的现场快速多模态谱学识别与新型杀灭技术”子课题 “电磁-新材料复合式病原体杀灭的机理研究”, 子课题编号: 2017YFC1200404-4, 经费190万元, 2017.10-2020.12. (负责人)

4) 国家自然科学基金: 新基因pOpR负调控金黄色葡萄球菌耐药性的作用与机制研究, 编号2016ZHZ01; 2017.1-2019.12, 50万元 (负责人)

5) 校科技成果转化基金: 登革热膜泡疫苗的工艺放大, 编号2016XZH01; 2017.1-2019.12, 50万元 (负责人)

6) 国家自然科学基金: 磷壁酸合成途径在万古霉素介导金黄色葡萄球菌耐药性中的作用与机制研究, 编号: 81471993; 2015-1-2018.12, 72万元 (负责人)

7) 教育部回国人员启动基金: 噬菌体Mmp1早期基因的鉴定及其在寄生宿主中作用的研究, 2013.01-2014.12, 3万元 (负责人)

8) 国家自然科学基金: 重组登革病毒膜泡疫苗的构建及其免疫效能研究, 编号: 31207097, 2013.1-2013.12; 15万元 (负责人)

9) 国家科技重大专项: 登革热膜泡疫苗的研究, 编号2012ZX0910301-038, 经费132.62万, 2012.1-2015.12 (负责人)

10) 国家自然科学基金: 新基因pOpR负调控金黄色葡萄球菌耐药性的作用与机制研究, 编号: 81471993; 2015-1-2018.12, 72万元 (负责人)

11) 军队XXX重大专项课题: 重要蚊传黄热病致病机制及嵌合假病毒研究, 编号: AWS11J01-07, 经费150万, 2011.1-2015.12 (负责人)

12) 国家自然科学基金: 登革-日本脑炎嵌合蛋白相互作用分子的筛选与鉴定, 编号: 31070811, 2011.1-2013.12, 经费30万元 (负责人)

13) 国家自然科学基金: 登革-日本脑炎嵌合蛋白相互作用分子的筛选与鉴定, 编号: 31070811, 2011.1-2013.12, 经费30万元 (负责人)